Survival outcomes for right- versus left-sided colon cancer and rectal cancer in patients receiving regorafenib and/or trifluridine/tipiracil for refractory metastatic colorectal cancer: Findings from the multicenter retrospective ReTrITa study.

被引：0

作者：

Signorelli, Carlo

Calegari, Maria Alessandra

Passardi, Alessandro

Lucchetti, Jessica

Zurlo, Ina Valeria

Morelli, Cristina

Dell'Aquila, Emanuela

Gemma, Donatello

Emiliani, Alessandra

Arrivi, Giulia

Zoratto, Federica

Chilelli, Mario Giovanni

Morandi, Maria Grazia

Santamaria, Fiorenza

Dettori, Manuela

Cosimati, Antonella

Saltarelli, Rosa

Minelli, Alessandro

Lucci-Cordisco, Emanuela

Basso, Michele

机构：

[1] ASL Viterbo, Belcolle Hosp, Med Oncol Unit, Viterbo, Italy

[2] Fdn Policlin Univ Agostino Gemelli, Comprehens Canc Ctr, Oncol Med, IRCCS, Rome, Italy

[3] IRCCS, Ist Romagnolo Studio Tumori IRST Dino Amadori, Dept Med Oncol, Meldola, Italy

[4] Policlin Univ, Div Med Oncol, Campus Biomed, Rome, Italy

[5] Vito Fazzi Hosp, Med Oncol, Lecce, Italy

[6] Tor Vergata Univ Hosp, Dept Syst Med, Med Oncol Unit, Rome, Italy

[7] IRCCS Regina Elena Natl Canc Inst, Rome, Italy

[8] ASL Frosinone, Med Oncol Unit, Sora, Italy

[9] Isola Tiberina Hosp, Med Oncol, Gemelli Isola, Rome, Italy

[10] Sapienza Univ Rome, St Andrea Univ Hosp, Dept Clin & Mol Med, Oncol Unit, Rome, Italy

[11] ASL Latina, Osped St Maria Goretti, UOC Oncol, Latina, Italy

[12] ASL Rieti, San Camillo Lellis Hosp, Med Oncol Unit, Rieti, Italy

[13] Sapienza Univ Rome, Dept Expt Med, UOC Oncol A, Policlin Umberto I Expt Med,Network Oncol & Precis, Rome, Italy

[14] Osped Oncol Armando Businco, Med Oncol Dept, Cagliari, Italy

[15] UO Oncol Universitaria Casa Salute Aprilia, Med Oncol Dept, Aprilia, Italy

[16] San Giovanni Evangelista Hosp, UOC Oncol, ASL RM5, Tivoli, Italy

[17] Osped San Paolo, Med Oncol Dept, UO Oncol, ASL RM4, Civitavecchia, RM, Italy

[18] Fdn Policlin Univ Agostino Gemelli, Dipartimento Sci V & San Pubbl, UOC Genet Med, IRCCS, Rome, Italy

[19] Fdn Policlin Univ Agostino Gemelli, Comprehens Canc Ctr, Med Oncol Dept, IRCCS, Rome, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期

关键词：

D O I：

10.1200/JCO.2025.43.4_suppl.67

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：67 / 67

页数：1

共 50 条

[11] Survival outcomes of left-sided versus right-sided colon cancer.
Gowarty, Jasmine Lizette
Durham, Charis
Wong, Lucas
Chen, Wencong
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[12] Predicting Trifluridine/Tipiracil Treatment Outcomes in Refractory Metastatic Colorectal Cancer Patients: A Multicenter Exploratory Analysis
Prejac, Juraj
Omcen, Tomislav
Radic, Jasna
Vrdoljak, Eduard
Frobe, Ana
Plestina, Stjepko
ONCOLOGY, 2024, 102 (03) : 217 - 227
[13] Characteristics and Outcomes of Right- Versus Left-Sided Early-Onset Colorectal Cancer
Tom, Cynthia M.
Mankarious, Marc M.
Jeganathan, Nimalan A.
Deutsch, Michael
Koltun, Walter A.
Berg, Arthur S.
Scow, Jeffrey S.
DISEASES OF THE COLON & RECTUM, 2023, 66 (04) : 498 - 510
[14] Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: a retrospective cohort study
Li, Rong-Rong
Zhou, Hui-Jun
Zeng, De-Yu
Jiang, Shao-Feng
Liu, Wu
Fruehling, Petter
Liu, Zhen-Yang
JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (02) : 612 - 629
[15] Effect of neutropenia on survival outcomes of patients with metastatic colorectal cancer receiving trifluridine/tipiracil plus bevacizumab
Kamiimabeppu, Daisaku
Osumi, Hiroki
Shinozaki, Eiji
Ooki, Akira
Wakatsuki, Takeru
Yoshino, Koichiro
Sato, Taro
Nakayama, Izuma
Ogura, Mariko
Takahari, Daisuke
Chin, Keisho
Yamaguchi, Kensei
ONCOLOGY LETTERS, 2021, 22 (05)
[16] Association between sidedness and survival among chemotherapy refractory metastatic colorectal cancer patients treated with trifluridine/tipiracil or regorafenib
Hsiao, Kai-Yuan
Chen, Hsin-Pao
Rau, Kun-Ming
Liu, Kuang-Wen
Shia, Ben-Chang
Chang, Wei-Shan
Liang, Hao-Yun
Hsieh, Meng-Che
ONCOLOGIST, 2024, 29 (12): : e1669 - e1679
[17] Effectiveness and safety of regorafenib and trifluridine/tipiracil in refractory metastatic colorectal cancer: A real-world multicenter retrospective study with focus on sequential treatment
Signorelli, C.
Schirripa, M.
Chilelli, M. G.
Calegari, M. A.
Basso, M.
Anghelone, A.
Lucchetti, J.
Minelli, A.
Angotti, L.
Morelli, C.
Dell'Aquila, E.
Cosimati, A.
Gemma, D.
Ribelli, M.
Corsi, D. C.
Arrivi, G.
Zoratto, F.
Morandi, M. G.
Santamaria, F.
Saltarelli, R.
Ruggeri, E. M.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S719 - S719
[18] Comparative analysis of clonal evolution among patients with right- and left-sided colon and rectal cancer
Banerjee, Santasree
Zhang, Xianxiang
Kuang, Shan
Wang, Jigang
Li, Lei
Fan, Guangyi
Luo, Yonglun
Sun, Shuai
Han, Peng
Wu, Qingyao
Yang, Shujian
Ji, Xiaobin
Li, Yong
Deng, Li
Tian, Xiaofen
Wang, Zhiwei
Zhang, Yue
Wu, Kui
Zhu, Shida
Bolund, Lars
Yang, Huanming
Xu, Xun
Liu, Junnian
Lu, Yun
Liu, Xin
ISCIENCE, 2021, 24 (07)
[19] Influence of age on disease control rate of patients treated with regorafenib and trifluridine/tipiracil in refractory metastatic colorectal cancer: A multicenter retrospective real-world study
Signorelli, C.
Calegari, M.
Basso, M.
Anghelone, A.
Lucchetti, J.
Minelli, A.
Angotti, L.
Zurlo, I.
Schirripa, M.
Chilelli, M.
Morelli, C.
Dell'Aquila, E.
Cosimati, A.
Gemma, D.
Ribelli, M.
Corsi, D.
Arrivi, G.
Zoratto, F.
Morandi, M.
Santamaria, F.
Saltarelli, R.
Ruggeri, E.
ANNALS OF ONCOLOGY, 2023, 34 : S85 - S85
[20] Efficacy of Chemotherapy Rechallenge Versus Regorafenib or Trifluridine/Tipiracil in Third-Line Setting of Metastatic Colorectal Cancer: A Multicenter Retrospective Comparative Study
Bazarbashi, Shouki
Alkhatib, Radwan
Aseafan, Mohamed
Tuleimat, Yasmin
Abdel-Aziz, Nashwa
Mahrous, Mervat
Elsamany, Sherif
Elhassan, Tusneem
Alghamdi, Mohammed
JCO GLOBAL ONCOLOGY, 2024, 10

← 1 2 3 4 5 →